Pregnancy glucagon-like peptide 1 predicts insulin but not glucose concentrations

• DOI: 10.1007/s00592-023-02142-8
• Publication Date: 2023-07-13T15:03:42Z
• Authors: Danielle L. Jones; Clive J. Petry; Keith Burling; Peter Barker; Elizabeth H. Turner; Laura C. Kusinski; Claire L. Meek
• Keywords: Incretin; Gastric inhibitory polypeptide; Glucose tolerance test

Incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory (GIP) cause increased insulin secretion in non-pregnant adults, but their role pregnancy, where there are additional metabolically-active from the placenta, is less clear. The aim of present study was to assess if fasting post-load incretin concentrations were predictive pregnancy glucose concentrations.Pregnant women (n = 394) with one or more risk factors for gestational diabetes recruited at 28 weeks a 75 g oral tolerance test (OGTT). Glucose, insulin, GLP-1 GIP measured state 120 min after ingestion.Fasting plasma associated (standardised β' 0.393 (0.289-0.498), p 1.3 × 10-12; n 306), not (p 0.3). association still evident when adjusting BMI (β' 0.271 (0.180-0.362), 1.1 10-8; 297). Likewise, OGTT 0.216 (0.100-0.331), 2.7 10-4; 306) even 0.178 (0.061-0.294), 2.9 10-3; 296), 0.9). either time point (all > 0.2). In GLP-1, GIP, appear be circulating concentrations, independently associations BMIs.These results suggest that relationship between incretins preserved other factors, such as placental counter-regulatory hormones, may important determinants glycaemia aetiology.